State Street Corp Brooklyn Immuno Therapeutics, Inc. Transaction History

State Street Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.48 - $2.03 $211,533 - $894,608	-440,694 Reduced 82.73%	91,997 $48,000
Q1 2022 May 16, 2022	BUY	$1.76 - $4.84 $41,242 - $113,415	23,433 Added 4.6%	532,691 $1.09 Million
Q4 2021 Feb 14, 2022	BUY	$4.17 - $9.79 $39,189 - $92,006	9,398 Added 1.88%	509,258 $2.12 Million
Q3 2021 Nov 15, 2021	BUY	$8.86 - $17.05 $538,377 - $1.04 Million	60,765 Added 13.84%	499,860 $4.65 Million
Q2 2021 Aug 16, 2021	BUY	$3.75 - $78.5 $1.65 Million - $34.5 Million	439,095 New	439,095 $7.91 Million

1.21M

Ticker BTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,825,700
Description
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy techno...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.